Comparing the New Blood Thinners to Warfarin
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 3, 2013 Category: Journals (General) Source Type: news

What Is Warfarin?
Warfarin is an anticoagulant medication - it is used to slow down the blood-clotting process. Anticoagulants are used to prevent blood clots which may cause vein blockages, heart attack and stroke. Warfarin is known under the brand names Warfant, Jantoven, Coumadin, Lawarin, Marevan, and Waran. Doctors prescribe warfarin for people who are at a higher risk of forming blood clots. Examples include patients with..: ..blood clots in the veins of the legs (deep vein thrombosis) ..a blood clot in the lungs (pulmonary embolism) ..an irregular heart beat (atrial fibrillation)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 1, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Comparing the New Blood Thinners to Warfarin
Find out how the new blood-thinning drugs Eliquis, Xarelto, and Pradaxa compare to warfarin. (Source: WebMD Health)
Source: WebMD Health - May 31, 2013 Category: Consumer Health News Source Type: news

Stroke Patients Likely Safe To Continue Blood Thinners Before Minor Surgery
A new guideline from the American Academy of Neurology advises that it is likely safe for patients to continue taking blood thinners like aspirin or warfarin before minor procedures such as a cataract operation, minor dental surgery or dermatological procedure. Developed with financial support from the American Academy of Neurology, the guideline appears in the 28 May issue of Neurology, the Academy's official journal... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 30, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

AAN: Don't Stop Warfarin for Dental Visits (CME/CE)
(MedPage Today) -- Patients taking aspirin or warfarin (Coumadin) for prevention after a stroke don't need to stop the drug for dental procedures, the American Academy of Neurology recommended. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 28, 2013 Category: Gastroenterology Source Type: news

2-Year-Old Drug Takes Top Rx Slot from Warfarin
(MedPage Today) -- The oral anticoagulant rivaroxaban (Xarelto) -- first approved by the FDA in 2011 -- is now being prescribed by cardiologists more often than warfarin, according to the latest figures from IMS NPA Weekly. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 25, 2013 Category: Primary Care Source Type: news

Molecular modelling to help create better, safer drugs
How our bodies break down the common drugs ibuprofen, diclofenac and warfarin is the subject of a new study from the University of Bristol, published in the Journal of the American Chemical Society. The research should ultimately help predict how new drugs will be metabolized in the body, potentially helping avoid adverse drug reactions in future. (Source: University of Bristol news)
Source: University of Bristol news - May 23, 2013 Category: Universities & Medical Training Authors: news_text Tags: Press releases Source Type: news

Catheter Ablation of AF Under Therapeutic WarfarinCatheter Ablation of AF Under Therapeutic Warfarin
Some electrophysiologists are still waiting for further evidence -- despite the compelling data. Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Low-intensity warfarin reduces bleeding, symptomatic venous thromboembolism after THA
Clark N. Thromb Res. 2013. doi:10.1016/j.thromres.2013.02.017. (Source: HemOncToday.com)
Source: HemOncToday.com - May 16, 2013 Category: Cancer & Oncology Source Type: news

Dabigatran "real-life" results suggest caution needed
New data from real-life experience of dabigatran for stroke prevention in AF shows that it is often used outside prescribing recommendations, and the risk of both thromboembolism and bleeding may be raised in patients switched from warfarin. (Source: theHeart.org)
Source: theHeart.org - May 15, 2013 Category: Cardiology Source Type: news

When the CHADS2 Score = 1: Will Aspirin Do or is Warfarin Indicated?
For a patient with atrial fibrillation whose risk of ischemic stroke is low, is antiplatelet therapy the right choice? A revised risk calcualation formula, based on the original CHADS2 criteria, restratifies low-risk patients to further select those who may not require oral anticoagulation. (Source: Consultant Live)
Source: Consultant Live - May 15, 2013 Category: Primary Care Source Type: news

Dabigatran 'Real Life' Results Suggest Caution NeededDabigatran 'Real Life' Results Suggest Caution Needed
New data from real-life experience of dabigatran for stroke prevention in AF show that it is often used outside prescribing recommendations, and the risk for both thromboembolism and bleeding may be raised in patients switched from warfarin. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Cardiac Device Surgery Without Interruption Of Warfarin Led To 80 Percent Reduction In Development Of A Significant Hematoma
A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care. The new findings were released at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, and are published online in The New England Journal of Medicine (NEJM). At least a quarter of patients that require pacemaker or implantable defibrillator surgery are taking warfarin to reduce the risk of a stroke... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 13, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Warfarin Beats Heparin Bridging for ICD/PM Implants Warfarin Beats Heparin Bridging for ICD/PM Implants
Guidelines recommend that patients at high risk for thromboembolic events be bridged with heparin therapy, but few randomized trials have compared this strategy with simply maintaining patients on warfarin for their procedures. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Warfarin discontinuation ‘unnecessary’ for pacemaker surgery
Warfarin should not be discontinued in favor of heparin before pacemaker or implantable cardioverter–defibrillator surgery in patients with a moderate-to-high risk for thromboembolism, the Bruise Control trial investigators recommend. (Source: MedWire News - Stroke)
Source: MedWire News - Stroke - May 11, 2013 Category: Neurology Source Type: news

Watchman Attains Efficacy Superiority Over Warfarin in AFWatchman Attains Efficacy Superiority Over Warfarin in AF
The Watchman left-atrial appendage occluder had previously been found noninferior to warfarin in patients with nonvalvular atrial fibrillation; now, with an average of 45 months of follow-up, it's not only noninferior, it's superior, by some statistical measures. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Encouraging 4 Year Results For Boston Scientific's Watchman Device In AF Patients
Encouraging long-term results from the PROTECT AF trial comparing the Watchman left atrial appendage closure device to warfarin in atrial fibrillation patients were presented yesterday at the Heart Rhythm Society meeting in Denver. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 10, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Warfarin discontinuation ‘unnecessary’ for pacemaker surgery
Warfarin should not be discontinued in favor of heparin before pacemaker or implantable cardioverter–defibrillator surgery in patients with a moderate-to-high risk for thromboembolism, the Bruise Control trial investigators recommend. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - May 10, 2013 Category: Cardiology Source Type: news

Continuous Warfarin Safer in Ablation (CME/CE)
DENVER (MedPage Today) -- Keeping warfarin (Coumadin) on board for an atrial fibrillation ablation procedure is safer than bridging with heparin, a randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 10, 2013 Category: Cardiology Source Type: news

Long-term PROTECT-AF analysis: Watchman attains efficacy superiority over warfarin in AF
The Watchman left-atrial appendage occluder had previously been found noninferior to warfarin in patients with nonvalvular atrial fibrillation; now, with an average of 45 months of follow-up, it's not only noninferior, it's superior, by some statistical measures. (Source: theHeart.org)
Source: theHeart.org - May 10, 2013 Category: Cardiology Source Type: news

PROTECT AF: Watchman Device Finally Superior (CME/CE)
DENVER (MedPage Today) -- The Watchman device saves lives and prevents strokes in atrial fibrillation better than warfarin (Coumadin) alone, longer-term results from the PROTECT AF trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 10, 2013 Category: Cardiology Source Type: news

Warfarin discontinuation ‘unnecessary’ for pacemaker surgery
Warfarin should not be discontinued in favor of heparin before pacemaker or implantable cardioverter–defibrillator surgery in patients with a moderate-to-high risk for thromboembolism, the Bruise Control trial investigators recommend. (Source: MedWire News - Stroke)
Source: MedWire News - Stroke - May 10, 2013 Category: Neurology Source Type: news

Device Surgery Best with No Coumadin Break (CME/CE)
DENVER (MedPage Today) -- Continuation of warfarin (Coumadin) through pacemaker or cardioverter-defibrillator procedures may be better for moderate-to-high risk patients than bridging with heparin, the randomized BRUISE CONTROL trial affirmed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 9, 2013 Category: Cardiology Source Type: news

Bruise Control: Continued Warfarin Beats Heparin Bridging During Device Implantation
Many patients receiving an ICD or a pacemaker are already receiving oral anticoagulants. Current guidelines recommend replacement of the oral anticoagulant with the temporary use of heparin as a bridging strategy. Now a new study, BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial), offers convincing evidence that this strategy is not beneficial and, in fact, results in an increase in device-pocket hematoma. Results of the trial were presented today at the Heart Rhythm Society meeting in Denver and published simultaneously in the New England Journal of Medicine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 9, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

BRUISE CONTROL: Continued warfarin beats heparin bridging in ICD/pacemaker implants
Guidelines recommend that patients at high risk for thromboembolic events be bridged with heparin therapy, but few randomized trials have compared this strategy with simply maintaining patients on warfarin for their procedures. (Source: theHeart.org)
Source: theHeart.org - May 9, 2013 Category: Cardiology Source Type: news

Operating without interrupting warfarin reduces risk of bleeding after cardiac device surgery
(University of Ottawa Heart Institute) A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care. The new findings were released today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, and will be published online today in The New England Journal of Medicine. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 9, 2013 Category: Global & Universal Source Type: news

Continued Warfarin Better Approach to Cardiac Device Surgery
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 9, 2013 Category: Primary Care Tags: Medical News Source Type: news

Apixaban (Eliquis) vs Warfarin Based on INR ControlApixaban (Eliquis) vs Warfarin Based on INR Control
The reduction in the primary efficacy end point of stroke or systemic embolism with apixaban was observed across a broad range of INR control in the warfarin-treated patients. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

New Design Mechanical Heart Valve Requires Low-Dose Anticoagulation Therapy, Decreases Bleeding Risk
For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation. Aggressive warfarin anticoagulation is accompanied by significant annual risk of bleeding, while inadequate anticoagulation of a mechanical artificial valve has been associated with high risk of clotting problems that can cause strokes... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 8, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Apixaban superior to warfarin across range of INR values, ARISTOTLE analysis
The reduction in the primary efficacy end point of stroke or systemic embolism with apixaban was observed across a broad range of INR control in the warfarin-treated patients. (Source: theHeart.org)
Source: theHeart.org - May 8, 2013 Category: Cardiology Source Type: news

Low-Dose Warfarin Seems Safe With Next-Gen Heart ValveLow-Dose Warfarin Seems Safe With Next-Gen Heart Valve
Interim results show reduced risk of bleeding and no increased risk of thromboembolism when aortic-valve-replacement patients receive less aggressive anticoagulant therapy. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 7, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

At last, an alternative to taking rat poison: The side effects of blood-thinner warfarin bring misery to thousands, but now there's another option
For thousands of Britons who suffer blood clots, warfarin is a lifeline. However, the potent drug is made from the same chemicals found in rat poison. (Source: the Mail online | Health)
Source: the Mail online | Health - May 6, 2013 Category: Consumer Health News Source Type: news

FDA OKs Kcentra for Fast Fix of Coumadin Bleeds
(MedPage Today) -- The FDA has approved Kcentra for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding, according to the agency. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 30, 2013 Category: Cardiology Source Type: news

Case report: hemodialysis for dabigatran overdose
3 out of 5 stars Hemodialysis for the Treatment of Pulmonary Hemorrhage from Dabigatran Overdose. Chen BC et al. Am J Kidney Dis 2013 Apr 15 [Epub ahead of print] Abstract Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved in the United States for stroke prophylaxis in patients with nonvalvular atrial fibrillation. Although dabigatran has certain advantages over coumadin related to issues of dosing and testing, there is no readily available test to measure its anticoagulation effect, and there is no antidote to reverse bleeding. Recommendations for treating a patient with dabigatran-associated he...
Source: The Poison Review - April 24, 2013 Category: Toxicology Authors: Leon Tags: Medical dabigatran hemodialysis hemorrhage overdose Source Type: news

New Drugs Better Value Than Warfarin (CME/CE)
(MedPage Today) -- The three newest anticoagulants -- dabigatran (Pradaxa), apixaban (Eliquis), and rivaroxaban (Xarelto) -- are cost-effective relative to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 9, 2013 Category: Cardiology Source Type: news

Interruption of Rivaroxaban vs Warfarin for AF: A Comparison of Risk
Post–hoc analysis of data from the ROCKET-AF trial found similar rates of stroke and systemic emboli after treatment interruption for rivaroxaban and warfarin in 2 out of 3 study cohorts. A very different result was found in the third. More, here. (Source: Consultant Live)
Source: Consultant Live - April 9, 2013 Category: Primary Care Source Type: news

Periprocedural dabigatran safe at AF ablation, with the right tweaks
It may be necessary to withhold only one dose prior to the procedure, a group concludes, having compared their dabigatran strategy with standard warfarin management. (Source: theHeart.org)
Source: theHeart.org - April 5, 2013 Category: Cardiology Source Type: news

Susceptibility To Some Viral Infections May Be Increased By Newly Approved Blood Thinner
A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults. For the past 50 years, people with the heartbeat irregularity, atrial fibrillation, and others at increased risk for forming potentially life-threatening blood clots have been given the anticoagulant drug warfarin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 3, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

CADTH review: Antithrombotic therapy for patients with atrial fibrillation
Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News The Canadian Agency for Drugs and Technologies in Health (CADTH) has published a review addressing the use of novel oral anticoagulants (NOAC) and antiplatelet agents for the management of patients with atrial fibrillation (AF). Evidence-informed recommendations were developed to address the following policy questions:   . In AF patients with a lower risk of stroke (CHADS2 score
Source: NeLM - Cardiovascular Medicine - March 26, 2013 Category: Cardiology Source Type: news

Systematic review and meta-analysis looks at risk factors for stroke in patients taking warfarin for AF
Source: Stroke Area: News The results of a systematic review and meta-analysis seeking to identify the risk factors that contribute to stroke risk in patients with atrial fibrillation (AF) who are taking an oral anticoagulant (OAC) have been published early online in the journal 'Stroke'.   The authors note that although OACs reduce the risks of stroke and mortality in patients with AF, some patients taking them will still sustain stroke.  They performed a systematic review to identify contemporary randomised clinical trials investigating OACs in patients with AF, and then performed a meta-analysis of recent...
Source: NeLM - Cardiovascular Medicine - March 25, 2013 Category: Cardiology Source Type: news

New Oral Anticoagulants in Secondary Stroke PreventionNew Oral Anticoagulants in Secondary Stroke Prevention
Should it be allowed, or not: combined analysis of three distinct trials testing different new oral anticoagulants in AF, suggesting how they collectively stack up against warfarin for secondary stroke prevention? Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

New oral anticoagulants in secondary stroke prevention: Apples and oranges?
Should it be allowed, or not: combined analysis of three distinct trials testing different new oral anticoagulants in AF, suggesting how they collectively stack up against warfarin for secondary stroke prevention? (Source: theHeart.org)
Source: theHeart.org - March 21, 2013 Category: Cardiology Source Type: news

Dabigatran May Cut Hospital Length of StayDabigatran May Cut Hospital Length of Stay
Warfarin can be more cumbersome to start and maintain patients on compared with the new generation of oral anticoagulants, which may give them a hospital length-of-stay edge in cases of new AF. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Dabigatran might cut hospital days vs standard anticoagulants in new AF
Warfarin can be more cumbersome to start and maintain patients on compared with the new generation of oral anticoagulants, which may give them a hospital length-of-stay edge in cases of new AF. (Source: theHeart.org)
Source: theHeart.org - March 14, 2013 Category: Cardiology Source Type: news

Horizon scanning: Phase II study of betrixaban vs. warfarin in patients with atrial fibrillation (Explore-Xa)
Source: Eur Heart J Area: News Betrixaban is an investigational once daily oral factor Xa inhibitor mostly excreted unchanged in the bile and with low (17%) renal excretion. The phase II study assessed its safety and tolerability at three different doses compared with warfarin in 508 patients with AF and more than one risk factor for stroke.   The patients had mean CHADS2 score of 2.2 and 87% had previously received vitamin K antagonist therapy. They were randomised to betrixaban 40, 60, or 80 mg once daily (n= 127 each dose) or unblinded warfarin, adjusted to an INR of 2.0-3.0 (n= 127). The primary outcome was m...
Source: NeLM - Cardiovascular Medicine - March 14, 2013 Category: Cardiology Source Type: news

Risk in Stopping Rivaroxaban and Warfarin Temporarily in AFRisk in Stopping Rivaroxaban and Warfarin Temporarily in AF
The temporary interruption resulted in very few strokes or thrombotic events and a low rate of bleeding in both rivaroxaban- and warfarin-treated patients. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Stopping rivaroxaban and warfarin temporarily in AF patients yields similar risks
The temporary interruption resulted in very few strokes or thrombotic events and a low rate of bleeding in both rivaroxaban- and warfarin-treated patients. (Source: theHeart.org)
Source: theHeart.org - March 10, 2013 Category: Cardiology Source Type: news

Safe Effective Warfarin Mgmt (Joshua Steinberg MD)
Hi folks, Here is the presentation I gave recently for our residents and students on safe effective use of Warfarin. It reviews a variety of clinical info necessary to be ready to manage Warfarin, and it is peppered with clinical cases to get people thinking and get them hungry to learn. Speaking of getting them hungry to learn, I start out with a pre-test in order to show the audience that they may not know enough to be ready to manage the medication. The presentation highlights issues on initiation and adjustment of Warfarin dosing according to the protocol we have adopted at our residency (from the AFP May '05 article)...
Source: Family Medicine Digital Resources Library (FMDRL) Recently Uploaded - March 4, 2013 Category: Primary Care Source Type: news

PROTECT AF: Watchman LAA Closure Ups QOL vs WarfarinPROTECT AF: Watchman LAA Closure Ups QOL vs Warfarin
Treatment with the percutaneous LAA-closure device had the edge in the trial's quality-of-life analysis, perhaps even more so in at least one subgroup. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Watchman ups quality of life vs chronic warfarin in nonvalvular AF: PROTECT AF
Treatment with the percutaneous LAA-closure device had the edge in the trial's quality-of-life analysis, perhaps even more so in at least one subgroup. (Source: theHeart.org)
Source: theHeart.org - February 27, 2013 Category: Cardiology Source Type: news